Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma? [0.03%]
黑色素瘤的综合化疗或大剂量干扰素Ⅱ目前还有作用吗?
Julie Fishman,Elizabeth I Buchbinder
Julie Fishman
Immune checkpoint inhibition and targeted therapies have revolutionized the treatment of melanoma. However, chemotherapy and interleukin 2 (IL-2) therapy may still have a role in the later-line treatment of patients who do not have durable ...
Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma [0.03%]
用于转移性黑色素瘤的肿瘤浸润淋巴细胞及其他细胞疗法
Christy Los,Sebastian Klobuch,John B A G Haanen
Christy Los
Major progress in prolonging survival of patients with advanced melanoma has been made in the past decade because of the development and approval of immune checkpoint inhibitor and targeted therapies. However, for nonresponding or relapsing...
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma [0.03%]
黑色素瘤转移期瘤内注射治疗的现状及作用
Alexandra M Haugh,Adil I Daud
Alexandra M Haugh
Intratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused o...
Afsaneh Amouzegar,Hussein A Tawbi
Afsaneh Amouzegar
Development of brain metastasis is one of the most serious complications of advanced melanoma, carrying a significant burden of morbidity and mortality. Although advances in local treatment modalities such as stereotactic radiosurgery and b...
Mali Barbi,Richard D Carvajal,Craig E Devoe
Mali Barbi
Uveal melanoma (UM), arising from intraocular melanocytes, poses a complex clinical challenge with a substantial risk of distant metastasis, often to the liver. Molecular profiling, encompassing genetic, cytogenetic, gene expression, and im...
What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma? [0.03%]
转移性黑色素瘤靶向治疗的时机和作用是什么?
Matthew J Hadfield,Ryan J Sullivan
Matthew J Hadfield
Melanoma is the most lethal cutaneous malignancy worldwide. The last 15 years have ushered in several regulatory approvals that have dramatically altered the landscape of treatment options for patients with melanoma. Many patients with mela...
Maya Dimitrova,Jeffrey Weber
Maya Dimitrova
Traditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab ove...
Madeline Miceli,Christina Boatwright,Janice M Mehnert
Madeline Miceli
This review outlines the most up-to-date metastatic melanoma treatment recommendations and relevant risks for patients with solid organ transplants, patients with renal dysfunction, and patients with preexisting autoimmune conditions. These...
Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches [0.03%]
III期可切除黑色素瘤的辅助和新辅助治疗
Ahmad A Tarhini,Ella Castellano,Islam Eljilany
Ahmad A Tarhini
Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micromet...
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease [0.03%]
局部晚期或远端转移性疾病患者的治疗方案
James W Smithy,Paul B Chapman
James W Smithy
The widespread adoption of immune checkpoint inhibitors and small molecule inhibitors of the MAP kinase pathway has transformed the management of locally advanced and metastatic melanoma. Here, we provide a broad overview on the use of thes...